Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sight Sciences Inc SGHT

Healthcare Medical Devices
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.


NDAQ:SGHT - Post by User

Sight Sciences Inc
Bullboard Posts
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jul 31, 2023 9:40am
95 Views
Post# 35564509

SIGHT SCIENCES: A VISIONARY IN THE FIELD OF OPHTHALMOLOGY

SIGHT SCIENCES: A VISIONARY IN THE FIELD OF OPHTHALMOLOGY
$SGHT

Excited to share an article about  Sight Sciences, Inc. (NASDAQ: SGHT), an eyecare technology company focused on creating innovative solutions to transform care and improve patients’ lives. The Company has focused initial product development efforts on treating two of the world’s most prevalent and underserved eye diseases, glaucoma and dry eye.

Sight Sciences is poised to seize a vast market opportunity with its unique and effective approved product offerings. It has also shown remarkable revenue growth over the last few years, making it a Company worth tracking.

Read on to know more:
https://www.aviseanalytics.com/sight-sciences-a-visionary-in-the-field-of-ophthalmology/
 
 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities